<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29211223</article-id><article-id pub-id-type="pmc">5701101</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Implantation of Cardioverter-Defibrillators Therapy
in Patients with Non-Ischemic Heart Failure: an Updated Systematic Review and
Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xing</surname><given-names>Zhenhua</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Liang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chenyang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jiabing</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Zhaowei</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Xinqun</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1">
<label>1</label> Second Xiangya Hospital of Central South University, Department
of Cardiology, Huan Province, P.R. China.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Xinqun Hu, Department of Cardiovascular
Medicine, The Second Xiangya Hospital, Central South University, Middle Ren-Min
road, No.139 - Changsha - Huan Province, P.R. China, Zip code: 410011. E-mail:
<email>xing2012x@163.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2017</year></pub-date><volume>32</volume><issue>5</issue><fpage>417</fpage><lpage>422</lpage><history><date date-type="received"><day>05</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Implantable cardioverter-defibrillator has become the first-line therapy for
prevention of sudden cardiac death. Controversial results still exist
regarding the effectiveness of implantable cardioverter-defibrillator (ICD)
in non-ischemic heart failure.</p></sec><sec><title>Methods</title><p>The PubMed, Embase, and Cochrane Central databases were searched for
randomized trials comparing implantable cardioverter-defibrillator in
combination with medical treatment <italic>versus</italic> medical treatment
for non-ischemic heart failure. The primary endpoint was incidence of
all-cause death. We derived pooled risk ratios with fixed-effects
models.</p></sec><sec><title>Results</title><p>Five studies enrolling 2573 patients were included. Compared with medical
treatment, implantable cardioverter-defibrillator with medical treatment was
associated with a significantly lower risk for all-cause mortality (Risk
ratio: 0.83; 95% confidence interval 0.71 to 0.97).</p></sec><sec><title>Conclusion</title><p>Compared with medical treatment only, implantable cardioverter-defibrillator
in combination with medical treatment reduces all-cause mortality.</p></sec></abstract><kwd-group><kwd>Defibrillators, Implantable</kwd><kwd>Heart Failure</kwd><kwd>Cardiomyopathies/*Therapy</kwd><kwd>Meta-Analysis</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="38%" span="1"/><col width="4%" span="1"/><col width="10%" span="1"/><col width="38%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AMIOVIRT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Amiodarone versus
Implantable Defibrillator Randomized Trial</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DEFINITE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Defibrillators in
Non-Ischemic Cardiomyopathy Treatment Evaluation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiomyopathy
trial</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Implantable
cardioverter-defibrillator</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COMPANION</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiac
resynchronization therapy</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RCTs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Randomized clinical
trials</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRTD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiac
resynchronization therapy-cardioverter&#x02013;defibrillator</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RRs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Risk ratios</td></tr><tr><td rowspan="2" align="left" style="background-color:#e6e7e8" colspan="1">CT</td><td rowspan="2" align="left" style="background-color:#e6e7e8" colspan="1">= Computed
tomographic</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SCD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Sudden cardiac
death</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SCD-HeFT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Sudden Cardiac Death in
Heart Failure Trial</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Sudden cardiac death (SCD) has become the leading cause of death in patients with
left ventricular dysfunction<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. A
large number of randomized clinical trials (RCTs) have proved that implantable
cardioverter-defibrillator (ICD) can terminate life-threatening ventricular
arrhythmias effectively and reduce mortality significantly<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Therefore, ICD has become the first-line therapy for
prevention of SCD for patients with heart failure and reduced left ventricular
systolic function in the U.S. and European guidelines. ICD gained a class 1
recommendation<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>]</sup>. However, the evidence in favor of
ICD is much stronger for patients with ischemic heart disease than it is for
patients with heart failure from other causes<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Over the past two decades, several RCTs concerning
non-ischemic heart failure were carried out with controversial results<sup>[<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r9" ref-type="bibr">9</xref>]</sup>. The cardiomyopathy trial (CAT), which randomly assigned 104
patients with recent onset of dilated cardiomyopathy and an ejection fraction
(&#x02264;30%) to receive ICD in combination with medical treatment or medical
treatment only did not show lower mortality with ICD<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Desai et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> performed a meta-analysis of 7 RCTs as regards ICD in
patients with non-ischemic heart failure and showed a significant 31% overall
reduction in mortality with ICD therapy. More confusingly, the recent Danish Study
to Assess the Efficacy of ICDs in Patients with non-ischemic Systolic Heart Failure
on Mortality (DANISH), which randomized 1,112 patients with symptomatic systolic
heart failure [ejection fraction (EF) 35%] to ICD in combination with optimal
medical treatment or optimal medical treatment only, did not provided evidence in
favor of ICD implantation<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Given
the confusing situation of ICD application in non-ischemic heart failure, we
performed an updated system review and meta-analysis.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Search Strategy and Selection Criteria</title><p>We systematically reviewed relevant studies between January 1, 1966, and August
31, 2016, by searching Embase, PubMed, and the Cochrane Central Register of
Controlled Trials. We used the terms implantable cardioverter-defibrillator,
implantable defibrillator, randomized controlled trial, and clinical trial to
identify RCTs. We considered all potentially eligible studies for review,
regardless of the primary outcome or language. We also performed a manual
search, by searching the reference lists of key studies.</p></sec><sec><title>Inclusion Criterion and Data Abstraction</title><p>We regarded studies as eligible for inclusion if they met the following criteria:
the study design was a prospective RCTs; the study population was non-ischemic
heart failure with high risk of SCD including symptomatic or asymptomatic
ventricular tachyarrhythmia or those with depressed left ventricular ejection
fraction (LVEF), patients were randomly assigned to ICD in combination with
medical therapy or medical therapy only; and the main endpoints included
all-cause mortality. If the study included patients with cardiac
resynchronization therapy (CRT) or cardiac resynchronization therapy-
cardioverter -defibrillator (CRTD), the proportion of patients with CRT or CRTD
should be matched between groups to eliminate the bias caused by CRT. Trials are
excluded if they contained survivors of SCD or unstable ventricular arrhythmias.
Trials which studied heart failure because of coronary artery disease are also
excluded.</p><p>Two investigators (L Tang and Zw Zhu) independently reviewed the articles
following the inclusion and exclusion criteria and assessed relevance of the
articles. Disagreements were resolved by discussion or consultation with a third
investigator (Xq Hu). The following data were abstracted from the selected
articles: total number of participants, inclusion criterion, study design, age,
sex, LVEF, New York Heart Association (NYHA) class, ICD type, duration of
follow-up, all-cause mortality and cardiac mortality.</p></sec><sec><title>Data Analysis</title><p>Meta-analysis was performed to calculate the risk ratio (RR) and 95% confidence
interval (CI) of all-cause mortality. Statistical heterogeneity among the
trial-specific RRs was checked and quantified by the I<sup>2</sup> statistic,
and a <italic>P</italic>-value &#x02264;0.05 was considered statistically
significant. When no significant statistical heterogeneity was identified, the
fixed effect was preferentially used; otherwise, a random-effects model was used
as an alternative. Data analysis will be performed on an intention-to-treat
basis. All analyses were performed using Review Manger Software, RevMan 5.3.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Search Results</title><p>The combined search strategy identified 1,208 potential relevant manuscripts. On
the basis of the abstract evaluation, 13 of these studies were considered
potentially eligible for inclusion and their full-texts were analyzed (<xref ref-type="fig" rid="f1">Figure 1</xref>). We excluded seven, four of them
studied the effectiveness of ICD in patients with ischemic heart failure, and
three were on the secondary prevention of ICD in patients with SCD. Cochrane
Collaboration's tool was used to assess risk of bias<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. After quality assessment, five high-quality
trials were eligible for further pooling analysis (<xref ref-type="fig" rid="f2">Figure 2</xref>). The main features of the five included studies have been
presented in <xref ref-type="table" rid="t1">Table 1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow diagram of literature searched for these reviews.</p><p>CRTD = Cardiac resynchronization
therapy-cardioverter-defibrillator</p></caption><graphic xlink:href="rbccv-32-05-0417-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Bias assessment using Cochrane Collaboration tool.</p></caption><graphic xlink:href="rbccv-32-05-0417-g02"/></fig>
</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Main features of included articles.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Inclusion criteria</th><th align="center" rowspan="1" colspan="1">Study design</th><th align="center" rowspan="1" colspan="1">Patients</th><th align="center" rowspan="1" colspan="1">ICD</th><th align="center" rowspan="1" colspan="1">Type of ICD</th><th align="center" rowspan="1" colspan="1">Follow-up (m)</th><th align="center" rowspan="1" colspan="1">Intention-to-treat</th><th align="center" rowspan="1" colspan="1">Controlled 1-y mortality (%)</th><th align="center" rowspan="1" colspan="1">Main result (RR reduction)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">CAT</td><td align="center" rowspan="1" colspan="1">EF&#x02264;0.35; NYHA II-III; DCM</td><td align="center" rowspan="1" colspan="1">ICD <italic>vs.</italic> drugs</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">ICD</td><td align="center" rowspan="1" colspan="1">66&#x000b1;26</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">54%</td></tr><tr><td align="center" rowspan="1" colspan="1">AMIOVIRT</td><td align="center" rowspan="1" colspan="1">EF&#x02264;0.35; DCM; NYHA II-III; asymptomatic
NSVT</td><td align="center" rowspan="1" colspan="1">ICD <italic>vs. </italic>amiodarone</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">ICD</td><td align="center" rowspan="1" colspan="1">24&#x000b1;16</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">No statistical significance</td></tr><tr><td align="center" rowspan="1" colspan="1">DEFINITE</td><td align="center" rowspan="1" colspan="1">EF&#x02264;0.35; DCM; NYHA I-III; NSVT</td><td align="center" rowspan="1" colspan="1">ICD <italic>vs.</italic> drugs</td><td align="center" rowspan="1" colspan="1">458</td><td align="center" rowspan="1" colspan="1">229</td><td align="center" rowspan="1" colspan="1">ICD</td><td align="center" rowspan="1" colspan="1">29&#x000b1;14</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">No statistical significance</td></tr><tr><td align="center" rowspan="1" colspan="1">SCD-HeFT</td><td align="center" rowspan="1" colspan="1">EF&#x02264;0.35; NYHA II-III</td><td align="center" rowspan="1" colspan="1">ICD <italic>vs</italic>. amiodarone
<italic>vs.</italic> placebo</td><td align="center" rowspan="1" colspan="1">1676</td><td align="center" rowspan="1" colspan="1">829</td><td align="center" rowspan="1" colspan="1">ICD</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">7.2</td><td align="center" rowspan="1" colspan="1">31%</td></tr><tr><td align="center" rowspan="1" colspan="1">DINISH</td><td align="center" rowspan="1" colspan="1">EF&#x02264;0.35;NICM;NT-proBNP&#x02265;200pg/ml</td><td align="center" rowspan="1" colspan="1">ICD/CRTD <italic>vs.</italic> drug/CRT</td><td align="center" rowspan="1" colspan="1">1116</td><td align="center" rowspan="1" colspan="1">556</td><td align="center" rowspan="1" colspan="1">ICD/CRTD</td><td align="center" rowspan="1" colspan="1">68&#x000b1;19</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">No statistical significance</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AMIOVIRT=Amiodarone vs. Implantable Defibrillator Randomized Trial;
CAT=cardiomyopathy trial; CRTD=cardiac resynchronization
therapy-cardioverter-defibrillator; DANISH=Danish Study; DCM=dilated
cardiomyopathy; DEFINITE=Defibrillators in Non-Ischemic
Cardiomyopathy Treatment Evaluation; LVEF=left ventricular ejection
fraction; NICM=non-ischemic systolic heart failure; NYHA=New York
Heart Association; NSVT=non-sustained ventricular tachycardia;
SCD-HeFT=Sudden Cardiac Death in Heart Failure Trial</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Characteristics of Studies</title><p>The five primary prevention of non-ischemic heart clinical trials are the
Cardiomyopathy Trial (CAT), the Amiodarone <italic>versus</italic> Implantable
Defibrillator Randomized Trial (AMIOVIRT), the Defibrillators in Non-Ischemic
Cardiomyopathy Treatment Evaluation (DEFINITE), the Sudden Cardiac Death in
Heart Failure Trial (SCD-HeFT), and the Danish Study (DANISH). Substantial
heterogeneity among studies was inevitable. The CAT, AMIOVIRT, and DEFINITE are
all patients with non-ischemic cardiomyopathy<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. However, the SCD-HeFT study
also included ischemic cardiomyopathy<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Only patients with non-ischemic cardiomyopathy were
included in the study. The DANISH trial randomized patients with non-ischemic
cardiomyopathy to ICD/CRTD in combination with optimal medical treatment, or
optimal drugs treatment/CRT<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.
Given the matching ratio of CRT or CRTD between ICD group and control group,
this trial was included. One other thing to note was that the Comparison of
Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) was
excluded, which randomly assigned patients with advanced heart failure to
optimal pharmacologic therapy alone or in combination with CRTD<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The COMPANION trial might
overstate the benefits of ICD in combination with function of resynchronized
pacing, as CRT alone already has a benefit on survival<sup>[<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Furthermore, patients with ischemic cardiomyopathy
was also included, which made data extract impossible. Last but not least, any
comparison of defibrillator with antiarrhythmic drugs reveals only the relative
effect of these two therapies, not the difference between treatment and no
treatment. The AMIOVIRT, SCD-HeFT both compared amiodarone with ICD which might
lead to bias inevitably. Given no beneficial effect of amiodarone on survival,
those studies were included<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
Finally, our meta-analysis included 2,573 patients with non-ischemic heart
failure randomized to ICD group or optimal pharmacologic therapy group (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline clinical characteristics of patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/><col width="9%" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1">Age (y)</th><th align="center" rowspan="2" colspan="1">Male (%)</th><th align="center" rowspan="2" colspan="1">EF (%)</th><th align="center" rowspan="2" colspan="1">No-ischemic (%)</th><th align="center" colspan="2" rowspan="1">NYHA (%)</th><th align="center" colspan="4" rowspan="1">Pharmacological therapy (%)</th></tr><tr><th align="center" rowspan="1" colspan="1">II</th><th align="center" rowspan="1" colspan="1">III</th><th align="center" rowspan="1" colspan="1">ACEI/ARB</th><th align="center" rowspan="1" colspan="1">&#x003b2;-blocker</th><th align="center" rowspan="1" colspan="1">Amiodarone</th><th align="center" rowspan="1" colspan="1">Digoxin</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">CAT</td><td align="center" rowspan="1" colspan="1">52&#x000b1;11</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="center" rowspan="1" colspan="1">AMIOVIRT</td><td align="center" rowspan="1" colspan="1">59&#x000b1;11</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">71</td></tr><tr><td align="center" rowspan="1" colspan="1">DEFINITE</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="center" rowspan="1" colspan="1">SCD-HeFT</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">47.3</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">67</td></tr><tr><td align="center" rowspan="1" colspan="1">DNISH</td><td align="center" rowspan="1" colspan="1">64&#x000b1;8</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ACE/ARB=angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker; AMIOVIRT=Amiodarone vs. Implantable Defibrillator
Randomized Trial; CAT=cardiomyopathy Trial; DANISH=Danish Study;
DEFINITE=Defibrillators in non-Ischemic cardiomyopathy treatment
evaluation; LVEF=left ventricular ejection fraction; NYHA=New York
Heart Association; SCD-HeFT=Sudden Cardiac Death in Heart Failure
Trial</p></fn></table-wrap-foot></table-wrap></sec><sec><title>All-Cause Mortality</title><p>The CAT, SCD-HeFT trials showed significant reduction in all-cause mortality with
RR reduction ranging from 31%-54%<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>. However, the
AMIOVIRT, DEFINITE, DANISH trials have not shown a statistical reduction in all
caused mortality<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. When the results of five randomized clinical trials
were pooled, no statistical evidence was found on the pooled evidence of
heterogeneity (I<sup>2</sup>=0, <italic>P</italic>=0.77). Pooled analysis using
a fixed-effects model showed the summary RR for all-cause mortality was 0.83
(95%CI: 0.65-0.96, <italic>P</italic>=0.02) (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>All-cause mortality among patients with non-ischemic heart disease
randomized to implantable cardioverter -defibrillator (ICD) vs.
medical treatment only in primary prevention.</p></caption><graphic xlink:href="rbccv-32-05-0417-g03"/></fig>
</p></sec><sec><title>SCD</title><p>The CAT and AMIOVIRT trails have not shown significant reduction in SCD. However,
a tendency towards a reduction in SCD by ICD therapy was found in the DEFINITE
and DANISH trials (RR: 0.2, CI: 0.06-0.71; RR: 0.50, CI: 0.31-0.82,
respectively). Only a substudy of the SCD-HeFT trial was included and we could
not extract the exact number of SCD in patients with non-ischemic heart failure.
This study was included when we calculated the pooled effects of SCD. Moderate
heterogeneity was found (I<sup>2</sup>=57%, <italic>P</italic>=0.1). Pooled
analysis using a random-effects model have not shown reduction in SCD (RR: 0.54,
CI: 0.21-1.37) (<xref ref-type="fig" rid="f4">Figure 4</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>SCD among patients with non-ischemic heart disease randomized to ICD
vs. medical treatment only in primary prevention.</p></caption><graphic xlink:href="rbccv-32-05-0417-g04"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our updated meta-analysis showed that, compared with optimized medical treatment, ICD
in combination with medical treatment can yield improved outcome in patients with
non-ischemic heart failure. In order not to overstate the benefits of ICD, the
COMPANION study was excluded which randomized patients to optimal medical treatment
in combination with CRTD or optimal medical treatment only. This analysis was robust
in sensitivity. Finally, it is important to notice that the benefit of ICD is less
compared with previous meta-analysis because of inclusion of the recent DANISH
study<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Over the past two decades, ICD implantation in patients with ischemic heart failure
has been associated with improved outcome. Theuns et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> performed a meta-analysis as regards ICD in
patients with ischemic heart disease. Pooled analysis showed a 29% RR reduction in
all-cause mortality. However, the effectiveness of ICD in patients with non-ischemic
heart failure is controversial. Meta-analysis of ICD secondary prevention trials
have not shown more benefits compared with medical treatment only<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. When new evidence occurs, we
performed an updated meta-analysis, and showed that ICD therapy in combination with
medical treatment improved outcome of patients with non-ischemic heart failure.</p><p>Our meta-analysis must be viewed in the context of its limitation. The treatment of
heart failure has improved greatly with the implication of CRT, beta-blocker, and
mineralocorticoid-receptor antagonist. Among this five RCTs, only CAT and SCD-HeFT
were in favor of ICD implantation. The CAT study was not important in the pooling
analysis because of its small sample size. The SCD-HeFT enrolled patients between
1997 and 2001, beta-blocker and mineralocorticoid-receptor antagonist were not well
managed among patients at that time. Furthermore, the differentiation between
ischemic heart and non-ischemic heart failure was mainly based on patient history,
which was quite inaccurate compared with coronary angiography or computed
tomographic (CT) angiogram used by the DANISH study. As we known, the evidence for a
benefit of ICD is much stronger for patients with ischemic heart failure. The
SCD-HeFT might overstate the benefits of ICD in patients with no-ischemic heart
failure. The DANISH study of which more patients accepted ACEI/ARB, beta-blocker,
mineralocorticoid-receptor antagonist, and CRT showed lowest mortality rate.</p><p>With optimized medical treatment in combined with CRT, ICD implantation in patients
with non-ischemic heart failure has not brought further benefits.</p><p>Second, given the small number of studies included, publication bias in favor of ICD
therapy cannot be inevitable. Although an extensive search strategy was performed,
some studies might not be included in this meta-analysis.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Although our finding lend support to the use of ICD in combination with optimal
medical treatment improves the outcome of non-ischemic heart failure, further
studies are needed to establish the optimal approach to treatment of non-ischemic
heart failure.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ZX</td><td align="left" valign="top" rowspan="1" colspan="1">Conception, acquisition, analysis,
interpretation of data, work review; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LT</td><td align="left" valign="top" rowspan="1" colspan="1">Conception, acquisition, analysis,
interpretation of data, work review; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CC</td><td align="left" valign="top" rowspan="1" colspan="1">Conception, acquisition, analysis,
interpretation of data, work review; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JH</td><td align="left" valign="top" rowspan="1" colspan="1">Conception, acquisition, analysis,
interpretation of data, work review; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZZ</td><td align="left" valign="top" rowspan="1" colspan="1">Conception, acquisition, analysis,
interpretation of data, work review; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">XH</td><td align="left" valign="top" rowspan="1" colspan="1">Conception, acquisition, analysis,
interpretation of data, work review; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the The Second Xiangya Hospital, Central South
University, Huan Province, P.R. China.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardy</surname><given-names>GH</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name><name><surname>Poole</surname><given-names>JE</given-names></name><name><surname>Packer</surname><given-names>DL</given-names></name><name><surname>Boineau</surname><given-names>R</given-names></name><etal/></person-group><article-title>Amiodarone or an implantable cardioverter-defibrillator for
congestive heart failure</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>3</issue><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">15659722</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name><name><surname>Higgins</surname><given-names>SL</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><etal/></person-group><article-title>Improved survival with an implanted defibrillator in patients
with coronary disease at high risk for ventricular arrhythmia. Multicenter
Automatic Defibrillator Implantation Trial Investigators</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><issue>26</issue><fpage>1933</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">8960472</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buxton</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Fisher</surname><given-names>JD</given-names></name><name><surname>Josephson</surname><given-names>ME</given-names></name><name><surname>Prystowsky</surname><given-names>EN</given-names></name><name><surname>Hafley</surname><given-names>G</given-names></name></person-group><article-title>A randomized study of the prevention of sudden death in patients
with coronary artery disease. Multicenter Unsustained Tachycardia Trial
Investigators</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>25</issue><fpage>1882</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">10601507</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yancy</surname><given-names>CW</given-names></name><name><surname>Jessup</surname><given-names>M</given-names></name><name><surname>Bozkurt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Drazner</surname><given-names>MH</given-names></name><etal/></person-group><article-title>2013 ACCF/AHA guideline for the management of heart failure: a
report of the American College of Cardiology Foundation/American Heart
Association Task Force on practice guidelines</article-title><source>Circulation</source><year>2013</year><volume>128</volume><issue>16</issue><fpage>e240</fpage><lpage>e327</lpage><pub-id pub-id-type="pmid">23741058</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Coats</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>2016 ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure: The Task Force for the diagnosis and treatment of
acute and chronic heart failure of the European Society of Cardiology (ESC).
Developed with the special contribution of the Heart Failure Association
(HFA) of the ESC</article-title><source>Eur J Heart Fail</source><year>2016</year><volume>18</volume><issue>8</issue><fpage>891</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">27207191</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f8;ber</surname><given-names>L</given-names></name><name><surname>Thune</surname><given-names>JJ</given-names></name><name><surname>Nielsen</surname><given-names>JC</given-names></name><name><surname>Haarbo</surname><given-names>J</given-names></name><name><surname>Videb&#x000e6;k</surname><given-names>L</given-names></name><name><surname>Korup</surname><given-names>E</given-names></name><etal/></person-group><article-title>Defibrillator implantation in patients with non-ischemic systolic
heart failure</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>13</issue><fpage>1221</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">27571011</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;nsch</surname><given-names>D</given-names></name><name><surname>Antz</surname><given-names>M</given-names></name><name><surname>Boczor</surname><given-names>S</given-names></name><name><surname>Volkmer</surname><given-names>M</given-names></name><name><surname>Tebbenjohanns</surname><given-names>J</given-names></name><name><surname>Seidl</surname><given-names>K</given-names></name><etal/></person-group><article-title>Primary prevention of sudden cardiac death in idiopathic dilated
cardiomyopathy: the Cardiomyopathy Trial (CAT)</article-title><source>Circulation</source><year>2002</year><volume>105</volume><issue>12</issue><fpage>1453</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">11914254</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strickberger</surname><given-names>SA</given-names></name><name><surname>Hummel</surname><given-names>JD</given-names></name><name><surname>Bartlett</surname><given-names>TG</given-names></name><name><surname>Frumin</surname><given-names>HI</given-names></name><name><surname>Schuger</surname><given-names>CD</given-names></name><name><surname>Beau</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Amiodarone versus implantable cardioverterdefibrillator:
randomized trial in patients with non-ischemic dilated cardiomyopathy and
asymptomatic nonsustained ventricular tachycardia: AMIOVIRT</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><issue>10</issue><fpage>1707</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">12767651</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Khatib</surname><given-names>SM</given-names></name><name><surname>Hellkamp</surname><given-names>AS</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Poole</surname><given-names>JE</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Implantable cardioverter defibrillator therapy in patients with
prior coronary revascularization in the Sudden Cardiac Death in Heart
Failure Trial (SCD-HeFT)</article-title><source>J Cardiovasc Electrophysiol</source><year>2008</year><volume>19</volume><issue>10</issue><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">18479330</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>AS</given-names></name><name><surname>Fang</surname><given-names>JC</given-names></name><name><surname>Maisel</surname><given-names>WH</given-names></name><name><surname>Baughman</surname><given-names>KL</given-names></name></person-group><article-title>Implantable defibrillators for the prevention of mortality in
patients with non-ischemic cardiomyopathy: a meta-analysis of randomized
controlled trials</article-title><source>JAMA</source><year>2004</year><volume>292</volume><issue>23</issue><fpage>2874</fpage><lpage>2879</lpage><pub-id pub-id-type="pmid">15598919</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Oxman</surname><given-names>AD</given-names></name><etal/></person-group><article-title>The Cochrane Collaboration's tool for assessing risk of bias in
randomised trials</article-title><source>BMJ</source><year>2011</year><volume>343</volume><elocation-id>d5928</elocation-id><pub-id pub-id-type="pmid">22008217</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadish</surname><given-names>A</given-names></name><name><surname>Dyer</surname><given-names>A</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name><name><surname>Quigg</surname><given-names>R</given-names></name><name><surname>Estes</surname><given-names>NA</given-names></name><name><surname>Anderson</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Prophylactic defibrillator implantation in patients with
non-ischemic dilated cardiomyopathy</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>21</issue><fpage>2151</fpage><lpage>2158</lpage><pub-id pub-id-type="pmid">15152060</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Erdmann</surname><given-names>E</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Gras</surname><given-names>D</given-names></name><name><surname>Kappenberger</surname><given-names>L</given-names></name><etal/></person-group><article-title>The effect of cardiac resynchronization on morbidity and
mortality in heart failure</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>15</issue><fpage>1539</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">15753115</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivero-Ayerza</surname><given-names>M</given-names></name><name><surname>Theuns</surname><given-names>DA</given-names></name><name><surname>Garcia-Garcia</surname><given-names>HM</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Simoons</surname><given-names>M</given-names></name><name><surname>Jordaens</surname><given-names>LJ</given-names></name></person-group><article-title>Effects of cardiac resynchronization therapy on overall mortality
and mode of death: a meta-analysis of randomized controlled
trials</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>22</issue><fpage>2682</fpage><lpage>2688</lpage><pub-id pub-id-type="pmid">16966347</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theuns</surname><given-names>DA</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Hunink</surname><given-names>MG</given-names></name><name><surname>Bardy</surname><given-names>GH</given-names></name><name><surname>Jordaens</surname><given-names>L</given-names></name></person-group><article-title>Effectiveness of prophylactic implantation of
cardioverter-defibrillators without cardiac resynchronization therapy in
patients with ischaemic or non-ischaemic heart disease: a systematic review
and meta-analysis</article-title><source>Europace</source><year>2010</year><volume>12</volume><issue>11</issue><fpage>1564</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">20974768</pub-id></element-citation></ref></ref-list></back></article>